179 related articles for article (PubMed ID: 15128066)
41. Reduced bone mass and preserved marrow adipose tissue in patients with inflammatory bowel diseases in long-term remission.
Bastos CM; Araújo IM; Nogueira-Barbosa MH; Salmon CEG; de Paula FJA; Troncon LEA
Osteoporos Int; 2017 Jul; 28(7):2167-2176. PubMed ID: 28405731
[TBL] [Abstract][Full Text] [Related]
42. Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.
Krela-Kaźmierczak I; Kaczmarek-Ryś M; Szymczak A; Michalak M; Skrzypczak-Zielińska M; Drwęska-Matelska N; Marcinkowska M; Eder P; Łykowska-Szuber L; Wysocka E; Linke K; Słomski R
Calcif Tissue Int; 2016 Dec; 99(6):616-624. PubMed ID: 27639566
[TBL] [Abstract][Full Text] [Related]
43. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease.
Schulte C; Dignass AU; Mann K; Goebell H
Inflamm Bowel Dis; 1998 Nov; 4(4):268-75. PubMed ID: 9836078
[TBL] [Abstract][Full Text] [Related]
44. [The risk factor for low bone mineral density in patients with inflammatory bowel disease].
Liu JB; Gao X; Zhang FB; Yang L; Xiao YL; Zhang RD; Li ZP; Hu PJ; Chen MH
Zhonghua Nei Ke Za Zhi; 2009 Oct; 48(10):833-6. PubMed ID: 20079225
[TBL] [Abstract][Full Text] [Related]
45. The frequency of osteoporosis screening in men with inflammatory bowel disease.
Nguyen HD; Bakshi AK; Borum ML
Am J Mens Health; 2010 Mar; 4(1):71-4. PubMed ID: 19477762
[TBL] [Abstract][Full Text] [Related]
46. Osteoporosis in inflammatory bowel disease.
Ali T; Lam D; Bronze MS; Humphrey MB
Am J Med; 2009 Jul; 122(7):599-604. PubMed ID: 19559158
[TBL] [Abstract][Full Text] [Related]
47. Osteoporosis in chronic liver disease.
Yadav A; Carey EJ
Nutr Clin Pract; 2013 Feb; 28(1):52-64. PubMed ID: 23263929
[TBL] [Abstract][Full Text] [Related]
48. Metabolic bone disease in adults with inflammatory bowel disease.
Adachi JD; Rostom A
Inflamm Bowel Dis; 1999 Aug; 5(3):200-11. PubMed ID: 10453377
[TBL] [Abstract][Full Text] [Related]
49. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
50. [THE DEFEAT OF BONE TISSUE IN CHILDREN WITH INFLAMMATORY BOWEL DISEASES].
Gabrusskaya TV
Eksp Klin Gastroenterol; 2016; (2):70-8. PubMed ID: 27301121
[TBL] [Abstract][Full Text] [Related]
51. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study.
Schulte C; Dignass AU; Mann K; Goebell H
Scand J Gastroenterol; 1999 Jul; 34(7):696-702. PubMed ID: 10466881
[TBL] [Abstract][Full Text] [Related]
52. Bone mineral metabolism in pediatric inflammatory bowel disease.
Issenman RM
Inflamm Bowel Dis; 1999 Aug; 5(3):192-9. PubMed ID: 10453376
[TBL] [Abstract][Full Text] [Related]
53. Bone Health in Patients With Inflammatory Bowel Diseases.
Chedid VG; Kane SV
J Clin Densitom; 2020; 23(2):182-189. PubMed ID: 31375349
[TBL] [Abstract][Full Text] [Related]
54. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Henderson S; Hoffman N; Prince R
Am J Gastroenterol; 2006 Jan; 101(1):119-23. PubMed ID: 16405543
[TBL] [Abstract][Full Text] [Related]
55. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria.
Kornbluth A; Hayes M; Feldman S; Hunt M; Fried-Boxt E; Lichtiger S; Legnani P; George J; Young J
Am J Gastroenterol; 2006 Jul; 101(7):1546-50. PubMed ID: 16863559
[TBL] [Abstract][Full Text] [Related]
56. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
Blair MM; Carson DS; Barrington R
J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
[TBL] [Abstract][Full Text] [Related]
57. [Glucocorticoid induced osteoporosis].
Anić B; Mayer M
Reumatizam; 2014; 61(2):105-12. PubMed ID: 25427404
[TBL] [Abstract][Full Text] [Related]
58. Discriminatory ability of calcaneal quantitative ultrasound in the assessment of bone status in patients with inflammatory bowel disease.
Turk N; Kastelan D; Cukovic-Cavka S; Kraljevic I; Korsic M; Vucelic B
Ultrasound Med Biol; 2007 Jun; 33(6):863-9. PubMed ID: 17434664
[TBL] [Abstract][Full Text] [Related]
59. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
60. Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area.
Ahmed SF; Horrocks IA; Patterson T; Zaidi S; Ling SC; McGrogan P; Weaver LT
J Pediatr Gastroenterol Nutr; 2004 Mar; 38(3):276-80. PubMed ID: 15076625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
